BARINTHUS Trademark

Trademark Overview

On Monday, January 8, 2024, a trademark application was filed for BARINTHUS with the United States Patent and Trademark Office. The USPTO has given the BARINTHUS trademark a serial number of 79392428. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Thursday, August 15, 2024. This trademark is owned by Barinthus Biotherapeutics (UK) Limited. The BARINTHUS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals; pharmaceutical preparations; pharmaceutical products; pharmaceuticals for the treatment and/or prevention of cancer, infectious diseases, and immune and autoimmune diseases; pharmaceutical preparations for the treatment and/or prevention of cancer, infectious diseases, and immune and autoimmune diseases; pharmaceutical products for the treatment and/or prevention of cancer, infectious diseases, and immune and autoimmune diseases; pharmaceuticals, pharmaceutical preparations and pharmaceutical products for the induction of immune tolerance; immunotherapeutics; immunotherapeutics for the treatment and/or prevention of cancer and infectious diseases, and immune and autoimmune diseases; vaccines; viral vaccines; vaccines for the treatment and/or prevention of influenza and other infectious diseases; vaccines for the treatment and/or prevention of cancer; viral antigens
barinthus

General Information

Serial Number79392428
Word MarkBARINTHUS
Filing DateMonday, January 8, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateThursday, August 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceuticals; pharmaceutical preparations; pharmaceutical products; pharmaceuticals for the treatment and/or prevention of cancer, infectious diseases, and immune and autoimmune diseases; pharmaceutical preparations for the treatment and/or prevention of cancer, infectious diseases, and immune and autoimmune diseases; pharmaceutical products for the treatment and/or prevention of cancer, infectious diseases, and immune and autoimmune diseases; pharmaceuticals, pharmaceutical preparations and pharmaceutical products for the induction of immune tolerance; immunotherapeutics; immunotherapeutics for the treatment and/or prevention of cancer and infectious diseases, and immune and autoimmune diseases; vaccines; viral vaccines; vaccines for the treatment and/or prevention of influenza and other infectious diseases; vaccines for the treatment and/or prevention of cancer; viral antigens

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 1, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBarinthus Biotherapeutics (UK) Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events

Event DateEvent Description
Tuesday, August 6, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, August 15, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, March 28, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, April 1, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, April 5, 2024APPLICATION FILING RECEIPT MAILED
Friday, August 2, 2024ASSIGNED TO EXAMINER
Monday, August 5, 2024NON-FINAL ACTION WRITTEN
Thursday, August 15, 2024REFUSAL PROCESSED BY MPU
Sunday, September 1, 2024REFUSAL PROCESSED BY IB

Related Keywords

barinthus diseases pharmaceutical prevention treatment infectious cancer immune vaccines autoimmune products